Kite Pharma
Gilead, Arcellx Outline Plans for Phase III Anito-Cel Multiple Myeloma Trial
The partners will compare the activity of the BCMA-directed autologous CAR T-cell therapy against standard treatment in refractory patients.
Sales of the firm's TROP2-directed antibody-drug conjugate climbed 56 percent year over year thanks to increased demand among breast and bladder cancer patients.
Gilead Lays off 7 Percent of Cell Therapy Staff to 'Optimize Operational Efficiency'
A spokesperson for the firm said Gilead is also adding 90 new employees to its cell therapy business unit Kite Pharma, making a net 5 percent total reduction.
Gilead Sciences, Epic Bio Ink Deal to Develop Improved CAR T-Cell Therapies
Gilead subsidiary Kite will use Epic Bio's gene expression modulation system to develop treatments including next-generation autologous CAR T-cell therapies.
Fosun Kite's CAR T-Cell Therapy Nets Second-Line Lymphoma Approval in China
Yikaida, which is known as Yescarta in other markets, is now available in China for large B-cell lymphoma patients after one treatment line.